SUMMARY BACKGROUND: Platelets are involved in the occlusion of coronary arteries after rupture of an atherosclerotic plaque. Furthermore, activated platelets release large quantities of growth factors, chemokines and interleukins that regulate inflammatory reactions. Therefore, we hypothesized that high basal platelet reactivity may contribute to an increased risk of myocardial infarction (MI) in premenopausal women. METHODS: We assessed the relation between high platelet reactivity and MI in a population-based case-control study among premenopausal women (aged < 50 years). We used multivariable logistic regression to quantify the effect of high platelet reactivity, adjusted for potential confounders. Platelet reactivity was estimated by plasma levels of neutrophil activating peptide 2 (NAP-2), CXC chemokine ligand (CXCL)4, soluble glycoprotein 1b (sGPIb) and soluble P-selectin. RESULTS: High platelet reactivity (i.e. levels >or= 90th percentile control subjects) was associated with a 2- to 3-fold increased incidence of MI: the adjusted odds ratios (ORs) were 3.0 [95% confidence interval (CI) 1.4-6.4] for NAP-2, 2.2 (0.9-5.1) for CXCL4, 1.9 (0.7-4.6) for sP-selectin and 2.5 (1.1-5.7) for sGPIb. The incidence of MI dose-dependently increased when more markers were elevated. High platelet reactivity according to both NAP-2 and sGPIb was associated with an up to tenfold increased incidence (9.9, 95% confidence interval 2.0-48.3). CONCLUSIONS: High basal platelet reactivity was associated with a 2- to 3-fold higher incidence of MI compared with normal platelet reactivity in premenopausal women. Our results suggest that high basal platelet reactivity may contribute to a higher risk of MI.
SUMMARY BACKGROUND: Platelets are involved in the occlusion of coronary arteries after rupture of an atherosclerotic plaque. Furthermore, activated platelets release large quantities of growth factors, chemokines and interleukins that regulate inflammatory reactions. Therefore, we hypothesized that high basal platelet reactivity may contribute to an increased risk of myocardial infarction (MI) in premenopausal women. METHODS: We assessed the relation between high platelet reactivity and MI in a population-based case-control study among premenopausal women (aged < 50 years). We used multivariable logistic regression to quantify the effect of high platelet reactivity, adjusted for potential confounders. Platelet reactivity was estimated by plasma levels of neutrophil activating peptide 2 (NAP-2), CXC chemokine ligand (CXCL)4, soluble glycoprotein 1b (sGPIb) and soluble P-selectin. RESULTS: High platelet reactivity (i.e. levels >or= 90th percentile control subjects) was associated with a 2- to 3-fold increased incidence of MI: the adjusted odds ratios (ORs) were 3.0 [95% confidence interval (CI) 1.4-6.4] for NAP-2, 2.2 (0.9-5.1) for CXCL4, 1.9 (0.7-4.6) for sP-selectin and 2.5 (1.1-5.7) for sGPIb. The incidence of MI dose-dependently increased when more markers were elevated. High platelet reactivity according to both NAP-2 and sGPIb was associated with an up to tenfold increased incidence (9.9, 95% confidence interval 2.0-48.3). CONCLUSIONS: High basal platelet reactivity was associated with a 2- to 3-fold higher incidence of MI compared with normal platelet reactivity in premenopausal women. Our results suggest that high basal platelet reactivity may contribute to a higher risk of MI.
Authors: Suzette J Bielinski; Cecilia Berardi; Paul A Decker; Phillip S Kirsch; Nicholas B Larson; James S Pankow; Michele Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Christina L Wassel; Joseph F Polak; Michael Y Tsai Journal: Atherosclerosis Date: 2015-02-23 Impact factor: 5.162
Authors: Alexander M Kollikowski; Mirko Pham; Alexander G März; Lena Papp; Bernhard Nieswandt; Guido Stoll; Michael K Schuhmann Journal: Transl Stroke Res Date: 2021-08-28 Impact factor: 6.800
Authors: Imo E Hoefer; Jan-Willem Sels; J Wouter Jukema; Sandrin Bergheanu; Erik Biessen; Elizabeth McClellan; Mat Daemen; Pieter Doevendans; Philip de Groot; Marieke Hillaert; Sebastiaan Horsman; Mustafa Ilhan; Johan Kuiper; Nico Pijls; Ken Redekop; Peter van der Spek; Andrew Stubbs; Eric van de Veer; Johannes Waltenberger; Anton-Jan van Zonneveld; Gerard Pasterkamp Journal: Clin Res Cardiol Date: 2013-08-23 Impact factor: 5.460
Authors: Jan-Willem E M Sels; Bert Rutten; Thijs C van Holten; Marieke A K Hillaert; Johannes Waltenberger; Nico H J Pijls; Gerard Pasterkamp; Philip G de Groot; Mark Roest Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Sophie Seang; Anoma Somasunderam; Maitreyee Nigalye; Ma Somsouk; Timoty W Schacker; Joyce L Sanchez; Peter W Hunt; Netanya S Utay; Jordan E Lake Journal: Pathog Immun Date: 2017-06-21